Modulating the Human Gut Microbiome and Health Markers through Kombucha Consumption: A Controlled Clinical Study

Abstract

Fermented foods are surging in popularity globally due to their links to metabolic health and the gut microbiome. However, direct clinical evidence for the health claims is lacking. Here, we describe an eight-week clinical trial that explored the effects of a kombucha supplement in healthy individuals consuming a Western diet, randomized into the kombucha ( n = 16) or control (n = 8) group. We collected longitudinal stool and blood samples to profile the human microbiome and inflammation markers. Paired analysis between baseline and end of intervention time points within kombucha or control groups revealed increases in fasting insulin and in HOMA-IR in the kombucha group whereas reductions in HDL cholesterol were associated with the control group. Shotgun metagenomic analysis revealed the relative abundance of Weizmannia, a kombucha-associated probiotic to be overrepresented in consumers at the end of the intervention. Short-term kombucha intervention induced modest impacts on human gut microbiome composition and biochemical parameters.

Highlights

• There is a global rise in popularity of fermented foods due to their links to metabolic health. However, empirical evidence supporting the health conferring benefits is lacking.

• This eight-week randomized controlled clinical trial tested the effect of kombucha on gut microbiome and inflammation in healthy participants consuming a Western diet.

• Biochemical indicators and inflammation markers were not different between the control and intervention groups at the end of the intervention.

• Kombucha-associated probiotic, Weizmannia and short chain fatty acids synthesizing microbes were enriched in consumers after 4 weeks of kombucha intervention.

• Download figure
• Open in new tab

Competing Interest Statement

Funding for this study was supported by GT living foods LLC. Jack Gilbert was on the scientific advisory board for GT living foods. GT was not involved in the analyses or presentation of the study data.

Clinical Trial

NCT06484504

Funding Statement

Funding for this study was supported by GT living foods LLC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research and related activities involving human subjects were approved by the Institutional Review Board at University of California, San Diego (IRB# 210823). All research, experiments and data analysis were performed in accordance with the University of California guidelines and regulations.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes